The Robert E. Fitzhenry Vector Laboratory is a leader in Canada’s immunotherapy development. It was the first academic GMP facility in the country to manufacture viral vectors approved by Health Canada for human clinical trials, starting in 2009. The laboratory supports translational medicine by offering virus-vector manufacturing services to researchers aiming to move their products into clinical trial testing.